Jefferies lifts Inovio price target to $8 after FDA approval of VOCERYQ
Jefferies raised its target price for Inovio Pharmaceuticals to $8 from $3 and kept a Buy rating following the FDA's clearance of VOCERYQ for recurrent respiratory papillomatosis. The analyst highlighted the drug's broad adult indication, lack of required surgery during treatment, and a planned price of $460,000 for a four‑dose course. Inovio estimates at least 25,000 adult patients in the United States. The firm also noted a recent capital raise that eases near‑term financing concerns.
Why it matters
The higher target suggests a potential re‑rating of Inovio's valuation, which could attract new buying interest. The price target increase reflects the market impact of the regulatory approval and the anticipated revenue from a $460,000 treatment price.
Key facts
- 1Jefferies raised its price target for Inovio to $8.00 from $3.00 and maintained a Buy rating. investing.com
- 2The FDA approved VOCERYQ, Inovio's therapy for recurrent respiratory papillomatosis. investing.com
- 3Inovio estimates at least 25,000 prevalent U.S. adult patients for the indication. investing.com
- 4Inovio plans to price VOCERYQ at $460,000 per four‑dose course. investing.com
- 5Jefferies said a recent capital raise removed key near‑term financing concerns. investing.com
- 6Jefferies' price‑target increase represents a 166.7% rise and implies a 558.4% upside from the Nov 6 close of $1.22. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.